Eye on FDA: What We Didn’t Hear at the FDA Part 15 Meeting on Social Media
We heard from far too few pharma companies, and far too many bloggers.
What was missing? What anyone should be doing in the meantime, what’s the process going forward, and what (if anything) is going on in Europe.